Gilead Sciences Inc (GILD) Earnings Report, Financial Results, Financial analysis

Gilead Sciences Inc reported in the first quarter of 2023 net earnings per share of $0.80 an increase by 3900 % year on year from $0.02 and decline of -38.34 % from $1.30 earned in IV. Quarter (Dec 31 2022).

*first quarter of 2023*
Earnings Per Share	Revenues
$ 0.8	$ 6,352 Mill
$+0.78 +3900 %	$-238M -3.61 %

Gilead Sciences Inc 's Revenue fell by -3.61 % in first quarter of 2023 (Mar 31 2023) year on year, to $6,352 million and declined by -14.03 % sequentially.

Gilead Sciences Inc is Expected to report next financial results on August 07, 2023.

More on GILD's Income Statement

GILD's NET INCOME

Gilead Sciences Inc 's net income of $985.000 million in the first quarter of 2023 increased by 8108.33 % from net earnings of $12.000 million achieved in I. Quarter a year ago.

Sequentially net earnings fell by -39.68 % from net income of $1,633.000 million realized in previous quarter.

More on GILD's Growth

Gilead Sciences Inc Inventories
Inventories grew by 6.34 % to $1,576 million from I. Quarter a year ago, sequentially inventories rose by 4.58 %. In Mar 31 2023 company's net cash and cash equivalents decreased by $-476 million, capital expenditures grew by -55.87%, to $-109 millions compare to same quarter a year ago and rose by -39.78% from IV. Quarter (Dec 31 2022).

More on GILD's Cash flow Statement

Earnings quality

Gilead Sciences Inc payed out dividend of $2.96 per share in last 52 weeks representing 66.82 % of net earning per share in trailing twelve-month period.

During the same period Gilead Sciences Inc earned $ 7.12 cash per share, on a free-cash flow basis 160.68 % of net earning per share.

Book value fell by -1.23 % sequentially to $16.61 per share.
Tangible Book value grew to $ -12.47 per share from $ -12.68.

Company repurchased 0.54 million shares or 0.04 % in Mar 31 2023.
Interest Coverage Ratio was 8.84. Debt Coverage Ratio was 0.32.

• More on GILD's Dividends

Market Capitalization (Millions)	98,062
Shares Outstanding (Millions)	1,261
Total Debt (Millions $)	25,239
Revenue (TTM) (Millions $)	27,043
Net Income (TTM) (Millions $)	5,539
Cash Flow (TTM) (Millions $)	640
Capital Exp. (TTM) (Millions $)	-590
Dividend TTM ($)	2.96 $
Dividend Yield TTM (%)	3.95 %
Employees (TTM) $	14,400

Earnings quality

Gilead Sciences Inc payed out dividend of $2.96 per share in the last 52 weeks representing 66.82 % of net earning per share in trailing twelve-month period.

During the same period Gilead Sciences Inc had $ 7.12 cash flow per share, on a free-cash flow basis 160.68 % of net earning per share.

Book value fell by -1.23 % sequentially to $16.61 per share.
Tangible Book value grew to $ -12.47 per share from $ -12.68.

Company repurchased 0.54 million shares or 0.04 % in Mar 31 2023.
Interest Coverage Ratio was 8.84. Debt Coverage Ratio was 0.32.

• More on GILD's Balance Sheets

Market Capitalization (Millions)	98,062
Shares Outstanding (Millions)	1,261
Total Debt (Millions $)	25,239
Revenue (TTM) (Millions $)	27,043
Net Income (TTM) (Millions $)	5,539
Cash Flow (TTM) (Millions $)	640
Capital Exp. (TTM) (Millions $)	-590
Dividend TTM ($)	2.96 $
Dividend Yield TTM (%)	3.95 %
Employees (TTM) $	14,400

Gilead Sciences Inc

GILD's Financial Statements and Analysis